The importation of drugs from lower-priced countries, like Canada, was an idea brought up during the Clinton Administration as a way for consumers to bypass the high cost of prescription drugs in the US. The effect of allowing importation is essentially about the imposition of a foreign drug price control on the US market. The economic analysis of the adverse effects of price controls on R&D and the diffusion of new drug technology is well-documented. It was a bad idea during the Clinton Administration, and it is still a bad idea today. This commentary white paper provides reasons why importation is still a bad idea today, but more importantly, why the reintroduction of this policy is a reflection of the broader effort against the industry to control drug prices and what pharma companies need to do to prepare against this existential threat to their business.
Complete the brief form to download the white paper.
Contact us at firstname.lastname@example.org with any questions.